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Background: Recurrent antimicrobial interventions and disease-related intestinal dysfunction are suspected to contribute to the dysbiosis of the
gastrointestinal microbial ecosystem in patients with cystic ﬁbrosis (CF). The present study set out to detect and identify microbial discriminants in
the gut microbiota composition that are associated with CF-related intestinal dysbiosis.
Methods: An in-depth description of CF-associated gut dysbiosis was obtained by screening denaturing gradient gel electrophoresis (DGGE)
ﬁngerprints for potentially discriminating bacterial species, and quantiﬁcation by means of real-time PCR analyses using group-speciﬁc primers.
Results: A total of 8 DGGE band-classes assigned to the genus Bifidobacterium (n=3), and members of Clostridium clusters XIVa (n=3) and IV
(n=2), were signiﬁcantly (pb0.05) underrepresented in samples of patients with CF. Real-time PCR analyses conﬁrmed a signiﬁcantly lower
abundance and temporal stability of biﬁdobacteria and Clostridium cluster XIVa in the fecal microbiota of patients with CF.
Conclusion: This study is the ﬁrst to report speciﬁc microbial determinants of dysbiosis in patients with CF.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Dysbiosis; Gut microbiota; DGGE; Real-time PCR1. Introduction
Chronic pulmonary infections in patients with cystic fibrosis
(CF) are controlled with frequent antimicrobial administration.
Although essential to restrain lung function decline, antimicro-
bial therapies disturb the balance of the gastrointestinal (GI)
microbial ecosystem, also known as GI dysbiosis.
In populations without underlying chronic diseases the
selective pressure of prolonged antibiotic treatment can trigger
a substantial reduction of metabolically important bacterial
groups [1,2], favor selection of antimicrobial resistant strains⁎ Corresponding author at: Faculty of Sciences, Laboratory of Microbiology,
K. L. Ledeganckstraat 35, 9000 Ghent, Belgium. Tel.: +32 9 264 5113;
fax: +32 9 264 50 92.
E-mail address: Peter.Vandamme@Ugent.be (P. Vandamme).
1569-1993/$ -see front matter © 2012 European Cystic Fibrosis Society. Published
http://dx.doi.org/10.1016/j.jcf.2012.10.003[3] and decrease colonization resistance, eliciting overgrowth
by potentially pathogenic microorganisms [4]. Moreover, several
studies have reported a long-term post-treatment perturbation
[5–8]. In young children, antibiotic-associated GI dysbiosis might
have severe consequences for their quality of life by disturbing the
maturation of the mucosa-associated lymphoid system [9–12] and
inadequate immune development [13,14], thus increasing the risk
for acquiring infections.
In addition to antimicrobial interventions, dysbiosis in patients
with CF could also result from the specific dietary regimen.
Several studies have indicated that a positive correlation exists
between alimentary habits early in life and improvement of CF
lung function through stimulation of the mucosal immune
defense maturation [15–17]. Furthermore, it has been shown
that GI dysbiosis can be induced by a high-fat, calorie-rich diet
[18].by Elsevier B.V. All rights reserved.
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fingerprinting we previously found evidence for a compositional
perturbation and substantially decreased temporal stability of the
fecal microbiota in a group of patients with CF [19]. We now
present the results of a follow-up study aiming at identifying
specific bacterial groups that can be considered determinants for
intestinal dysbiosis in patients with CF.2. Materials and methods
2.1. Ethics statement
All eligible candidates for this survey and their parents
received written information detailing the intent of the study. As
the study only included a non-invasive sampling procedure for
which the participants' willingness to provide the samples was
mandatory, the Ethics Committee of the University of Leuven,
Belgium, approved the verbal informed consent obtained from
both parents/guidance and participating children (no. ML4698).2.2. Participants
Fecal samples of 21 family units were analyzed in this study.
A family unit was defined as one patient with CF and one to
two healthy siblings. All patients had a history of antibiotic
treatment prior to and/or during the sampling period [19]. For 9
of these family units, 4 to 8 fecal samples collected between
2007 and 2009 were analyzed in a longitudinal study (Table 1);
in addition, one sample of each of the study participants was
analyzed in a cross-sectional study.Table 1
Clinical characteristics of patients with CF and healthy siblings in the longitudinal s
Family unit Gender CFTR genotype a Year of birth
3 Patient F F508del/C276X 1994
Sibling F / 1998
5 Patient F N1303K/F508del 1998
Sibling F / 2006
6 Patient F F508del/F508del 2005
Sibling F / 2001
Sibling F / 2004
10 Patient M F508del/G542X 1996
Sibling M / 1994
11 Patient F F508del/F508del 2005
Sibling F / 2001
14 Patient F F508del/F508del 1997
Sibling F / 1995
16 Patient F F508del/2183AANG 2003
Sibling F / 1998
18 Patient M F508del/F508del 1996
Sibling F / 1992
19 Patient F F508del/F508del 1998
Sibling F / 1992
a CFTR mutation data of siblings were not displayed for confidentiality reasons.
b Age at the first sampling point.
c Antibiotic administration before and during sampling. For details see supplemen2.3. Sample preparation
Stool samples were thawed at room temperature, and 1 g (wet
weight) was homogenized in 9 ml peptone buffered saline (PBS)
(0.1% w/v bacteriological peptone [catalog no. L37; Oxoid,
Basingstoke, UK], 0.85% w/v NaCl). 1 ml of the resulting fecal
solution was used for DNA extraction as previously described
[20,21].
2.4. Denaturing gradient gel electrophoresis (DGGE)
Cross-sectional studyDGGE fingerprints of 21 patients with CF
and 24 healthy siblings, and longitudinal study DGGE fingerprints
of 2 family units were available from a previous study [19]. Novel
DGGE-PCR experiments were performed as previously described
[19], on longitudinal samples from 7 additional family units using
universal bacterial primers targeting the hyper-variable V3 region
of the 16S rRNA gene. The resulting 16S rRNA amplicons were
separated by DGGE fingerprinting using the D-code System
(Bio-Rad, Nazareth, Belgium) with a 35–70% linear gradient
(100% denaturing polyacrylamide solution containing 7 M urea
(EC-605, National Diagnostics) and 40% formamide (F-9037,
Sigma, St. Louis, USA)).
2.5. DGGE gel band matching, extraction and sequencing
Upon normalization, all fingerprint profiles were subjected
to band-class analysis as described by Joossens and coworkers
[22]. Non-parametric Mann–Whitney-U tests were performed
to screen for potentially discriminating band-classes in fingerprint
profiles of patients with CF and healthy siblings. p-Values of less
than 0.05 were considered significant and multiple-testing errorstudy.
Age (years) b Sampling period Antibiotic history c
12.8 Oct/07–Aug/09 Aug/07–Aug/09
9.6 Aug/07–Aug/09 N/A
8.6 Jul/07–Jan/09 May/07–Apr/09
0.8 Jul/07–Jan/09 Oct/07–Sept/08
1.7 Jul/07–Aug/09 Apr/07–Sep/07
5.6 Jul/07–May/08 N/A
3.4 Jul/07–Feb/08 Feb/08
11.6 Nov/07–Nov/08 Jul/08–Nov/08
13.2 Nov/07–Nov/08 Feb/08
2.4 Aug/07–May/09 Apr/07–Jul/09
6.1 Aug/07–May/09 N/A
10.5 Sep/07–Aug/08 Jun/08–Sep/08
12.5 Sep/07–Feb/09 Dec/02 and Apr/08–May/08
3.9 Oct/07–Apr/09 Aug/07–Jun/08 and Oct/08
8.8 Oct/07–Apr/09 Jan/09
11.7 Dec/07–Nov/08 Sep/07–Oct/09
15.7 Dec/07–Mar/09 N/A
9.4 Dec/07–Feb/09 Nov/07–Feb/09
15.6 Dec/07–Feb/09 Oct/08–Nov/08
tary Table S1.
Table 2
Distribution of discriminating band-classes per family unit included in the longitudinal study.
Family unit Band-class Samples of patients with CF Samples of healthy siblings p-Value a p-Adjusted b
No. of positive samples Median band intensity
(min–max)
No. of positive samples Median band intensity
(min–max)
3 8.90 0/7 0 (0–0) 7/8 12.18 (0–33.21) 0.002 0.012
10.22 0/7 0 (0–0) 6/8 5.01 (0–24.10) 0.014 0.028
14.02 1/7 0 (0–4.72) 7/8 3.81 (0–27.13) 0.014 0.028
6 c 8.90 0/5 0 (0–0) 3/3 6.00 (5.46–15.53) 0.036 0.144
3/3 13.54 (10.96–20.63) 0.036 0.142
11 3.79 0/8 0 (0–0) 7/8 7.10 (0–10.21) 0.002 0.006
8.90 1/8 0 (0–0.11) 6/8 1.2 (0–11.81) 0.015 0.03
9.46 1/8 0 (0–6.49) 8/8 7.10 (1.78–16.26) 0.002 0.006
10.22 0/8 0 (0–0) 5/8 5.29 (0–12.17) 0.038 0.051
16.05 0/8 0 (0–0) 7/8 10.02 (0–28.44) 0.002 0.006
16.27 1/8 0 (0–7.14) 8/8 22.16 (9.68–35.72) 0.000115 0.00186
14 8.90 1/5 0 (0–8.30) 7/7 7.32 (2.86–4.35) 0.03 0.1
11.46 0/5 0 (0–0) 6/7 2.81 (0–9.65) 0.01 0.05
16.27 0/5 0 (0–0) 7/7 13.78 (0–54.43) 0.01 0.05
16 8.90 1/6 0 (0–10.37) 7/7 15.68 (3.10–21.26) 0.005 0.027
16.27 0/6 0 (0–0) 7/7 20.14 (9.87–29.05) 0.001 0.008
18 14.02 4/4 2.43 (0.30–2.65) 5/5 8.63 (2.53–24.81) 0.032 0.221
a p-Values are based on non-parametric Mann–Whitney-U tests (95% C.I.).
b Adjusted p-values are based on Benjamini–Hochberg correction for multiple testing.
c Family unit consisting of one patient with CF and two healthy siblings.
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[23]. Bands representing potentially discriminating band-classes
were excised from the DGGE gel and sequenced as previously
described [24]. The web-based EzTaxon Server v2.1, a manually
annotated and curated database of 16S ribosomal RNA gene
sequences for bacterial type strains with validly described species
names, was used to allocate sequenced bands to species based on
16S rRNA gene sequence similarities [25]. The V3-16S rRNA
gene sequences determined in this study have been deposited
in the EMBL database under accession numbers HE617671 to
HE617678.2.6. Real-time PCR
Based on the results of DGGE band discriminant analysis,
concentrations of fecal bifidobacteria and members of Clostridium
cluster XIVa were determined with real-time PCR using the
LightCycler system I (Roche, Mannheim, Germany) and the
SensiMix™ Capillary Kit (QT405-05, Bioline, London, UK).
Bifidobacteria were quantified using Bifidobacterium-specific
primers g-Bifid-F (5′ CTCCTGGAAACGGGTGG 3′) and
g-Bifid-R (5′ GGTGTTCTTCCCGATATCTACA 3′) [26],
and a calibration curve was constructed based on a serial
dilution of DNA from Bifidobacterium breve LMG 13208T
from which anaerobic plate counts were obtained on Modified
Columbia agar [27]. For quantification of Clostridium cluster
XIVa members, previously described group-specific primers
g-Ccoc-F (5′ AAA TGA CGG TAC CTG ACT AA 3′) and
g-Ccoc-R (5′ CTT TGA GTT TCA TTC TTG CGA A 3′) were
used [28] and anaerobic enumeration of Ruminococcus torques
strain L2–14 onto medium YCFAGSC [29] was performed forconstruction of the calibration curve. The 20 μl reaction mixture
contained 4 μl SensiMix™ Lite (Bioline Ltd., London, UK),
0.4 μl 50*SYBR®Green I solution (Bioline Ltd.), 1.5 μl enzyme
mix (Bioline Ltd.), 8.1 μl MQ water, 5 μM of each primer
(Sigma Aldrich, Bornem, Belgium) and 2 μl bacterial DNA. The
real-time PCR program consisted of initial denaturation at 94 °C
for 5 min, followed by 40 cycles of denaturation for 20 s at
94 °C, annealing at 65 °C (genus Bifidobacterium) or 55 °C
(Clostridium cluster XIVa) for 20 s and elongation at 72 °C
for 50 s. SYBR green fluorescence was detected at the end of
each amplification step. Melting curve analyses were performed
by slowly increasing the temperature from 60 °C to 95 °C
(genus Bifidobacterium) or 75 °C to 95 °C (Clostridium
cluster XIVa). Measurements were performed in triplicate,
and were repeated when variation between measurements
exceeded 0.5 Ct.2.7. Statistical analyses of real-time PCR data
The longitudinal datasets were analyzed with a linear mixed
model that accounts for the temporal variation between con-
secutive samples of each subject nested within a family unit.
Samples of the cross-sectional study were compared with
parametric one-tailed paired t-tests. In addition, the effect of
several clinical parameters including forced expiratory volume
in one second (FEV1), forced vital capacity (FCV), age, weight
for height and gender was assessed. Statistical analyses were
performed using SAS version 9.4 with p-values of less than
0.05 considered significant. Fecal concentrations were ex-
pressed as log10 colony forming units (CFU) per gram wet
weight stool.
Fig. 1. DGGE fingerprint profiles of the longitudinal study. DGGE fingerprint profiles showing the predominant fecal microbiota of a) family unit 3; b) family unit 6;
c) family unit 11; d) family unit 14; e) family unit 16; and f) family unit 18, and discriminating band-classes. Bc: band-class, S1 to 8: sample 1 to 8, CF: patient with
CF; SIBLING: healthy sibling.
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3.1. DGGE fingerprint analysis of longitudinal samples
The DGGE study of nine family units, in which per subject 4
to 8 samples obtained over a two year period were included,
yielded a total of 103 DGGE profiles which were investigated for
the presence of potentially discriminating band-classes. The total
number of band-classes present in more than half of the CF
samples or sibling samples, ranged from 6 to 24 per family unit.
Statistical analysis of these band-classes revealed significant
differences between samples of patients with CF and healthy
siblings (Mann–Whitney-U test, pb0.05) in six family units,
with each unit displaying 1 to 7 potentially discriminating bands.
Benjamini–Hochberg correction for multiple testing reduced
these results to five family units with the number of significant
band-classes ranging from 1 to 6 per family unit (Table 2).
For each of these discriminating band-classes, bands weresignificantly more represented in sibling samples compared to
samples of the corresponding patient with CF (Fig. 1). In total
8 different band-classes displayed a significant difference
between samples of patients with CF and healthy siblings:
band-class 8.90 was significantly underrepresented in fecal
samples of patients in five out of the six family units,
band-class 16.27 was discriminative in three family units,
band-classes 10.22 and 14.02 were underrepresented in patient
samples of 2 family units, and band-classes 3.79, 9.46, 11.46 and
16.05 were underrepresented in one family unit only.
Sequence analysis of DNA amplicons corresponding to band-
classes 14.02, 16.05 and 16.27 revealed 100% 16S rRNA gene
sequence identity with Bifidobacterium longum, Bifidobacterium
catenulatum/Bifidobacterium pseudocatenulatum/Bifidobacterium
kashiwanohense (the 140–144 bp V3−16S rRNA fragment does
not allow differentiation of closely related bacterial species) and
Bifidobacterium adolescentis/Bifidobacterium ruminantium/
Bifidobacterium stercoris, respectively (Table 3). Subsequent
Table 3
EzTaxon-identifications of V3-16S rRNA gene sequences for the different band-classes.
Band-class # of base pairs Accession no Closest related type species|accession number Pairwise similarity (%)
3.79 136 HE617671 Ruminococcus bromii ATCC 2755T|L76600 97.794
8.90 135 HE617672 Eubacterium fissicatena DSM 3598T|FR749935 100.000
Eubacterium contortum DSM 3982T|FR749945 100.000
Clostridium oroticum DSM 1287T|FR749917 100.000
9.46 136 HE617673 Blautia stercoris GAM6-1T|HM626177 100.000
Blautia luti BInIXT|AJ133124 100.000
Blautia hansenii DSM 20583T|ABYU01000028 100.000
Blautia schinkii BT|X94965 100.000
Blautia coccoides ATCC 29236T|M59090 100.000
10.22 135 HE617674 Ruminococcus lactaris ATCC 29176T|ABOU02000049 99.259
Ruminococcus gauvreauii CCRI-16110T|EF529620 99.259
Eubacterium xylanophilum ATCC 35991T|L34628 99.259
Clostridium herbivorans 54408T|L34418 99.259
Acetivibrio ethanolgignens DSM 3005T|FR749897 99.259
11.46 135 HE617675 Faecalibacterium prausnitzii ATCC 27768T|AJ413954 98.519
14.02 140 HE617676 Bifidobacterium longum subsp. longum JCM 1217T|AP010888 100.000
16.05 142 HE617677 Bifidobacterium pseudocatenulatum DSM 20438T|ABXX02000002 100.000
Bifidobacterium catenulatum DSM 16992T|ABXY01000019 100.000
Bifidobacterium kashiwanohense HM2-2T|AB491757 100.000
16.27 144 HE617678 Bifidobacterium adolescentis ATCC 15703T|AP009256 100.000
Bifidobacterium ruminantium JCM 8222T|D86197 100.000
Bifidobacterium stercoris Eg1T|FJ611793 100.000
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strains of these Bifidobacterium species, indicated that only
B. adolescentis co-migrated with band-class 16.27, and that
only B. catenulatum and B. pseudocatenulatum co-migrated with
band-class 16.05 (Fig. S1). We therefore tentatively identified
the bacteria represented by band-classes 14.02, 16.05 and
16.27 as B. longum, B. catenulatum/B. pseudocatenulatum and
B. adolescentis, respectively.
In addition, DNA amplicons corresponding to band-classes
3.79 and 11.46 showed the highest sequence similarity with
Ruminococcus bromii (97.8%) and Faecalibacterium prausnitzii
(98.5%), respectively (Table 3). Both species are members of
Clostridium cluster IV [31]. DNA amplicons corresponding to
band-class 8.90 showed 100% sequence similarity with
Eubacterium contortum, Clostridium oroticum and Eubacte-
rium fissicatena; DNA amplicons of band-class 9.46 showed
100% sequence similarity to five species of the genus Blautia
(Table 3), and DNA amplicons corresponding to band-class
10.22 showed 99.3% sequence similarity to five different species,
namely Ruminococcus lactaris, Ruminococcus gauvreauii, Eu-
bacterium xylanophilum, Clostridium herbivorans and Acetivibrio
ethanolgignens, of which the latter three have not been isolated
from human stool before. Band-classes 8.90, 9.46 and 10.22 each
represent members of Clostridium cluster XIVa [31].3.2. DGGE fingerprint analysis of cross-sectional samples
In parallel with the longitudinal study, a cross-sectional dataset
consisting of 42 samples from 20 patients with CF and 22 siblings
was screened for potentially discriminating band-classes. Howev-
er, none of the band-classes was found to represent a significant
difference between both groups.3.3. Real-time PCR analyses
The 8 discriminative DGGE band-classes identified in this
study represent three major components of the human GI
microbiota, namely the genus Bifidobacterium and Clostrid-
ium clusters IV and XIVa [31]. Subsequent quantification
experiments did not include Clostridium cluster IV as it was
represented by two band-classes, each detected in only one
family unit, whereas Bifidobacterium band-classes (i.e. 14.00,
16.05 and 16.27) were significantly underrepresented in fecal
samples of patients with CF in 5 out of the 6 family units and
Clostridium cluster XIVa band-classes (i.e. 8.90, 9.46 and
10.22) were significantly underrepresented in samples of pa-
tients with CF in all but one family unit.
Fig. 2 shows the temporal variation of bifidobacterial
abundance in the five family units where bifidobacteria were
significantly underrepresented as determined by band-class a-
nalysis. CF samples consistently displayed lower bifidobacterial
concentrations (Fig. 2). In addition, although not statistically
significant (linear mixed model, p=0.16) visual inspection of
these data revealed a stronger temporal variation in bifidobacterial
abundance in samples of patients with CF compared to healthy
siblings throughout (Fig. 2).
Furthermore, a cross-sectional analysis was conducted
investigating the first sample of 21 family units. Although
DGGE band-class analysis did not reveal any discriminatory
potential of bifidobacteria, real-time PCR analysis revealed a
significantly higher Bifidobacterium abundance in samples
from healthy siblings (8.71± 0.13 mean log10 CFU/g stool)
compared to patient samples (7.97±0.26 mean log10 CFU/g
stool) (one-tailed paired t-test, p = 0.003) (Fig. 3).
Fig. 4 shows the temporal variation of the Clostridium cluster
XIVa abundance in the five family units where these bacteria
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CF. In addition, analysis of the temporal variation of Clostridium
cluster XIVa abundance per family unit again revealed a higher
temporal variation between the different sampling points of the
patients with CF compared to their healthy siblings (Fig. 4),
which however, was not significant between both groups (linear
mixed model, p=0.39).
Although members of Clostridium cluster XIVa were not
discriminatory in the cross-sectional dataset using DGGE band
class analysis, real-time PCR analysis revealed a significantly
lower abundance of these bacteria in samples of patients with CF
(6.51±0.17 mean log10 CFU/g stool) compared to samples of
healthy siblings (7.14±0.09 mean log10 CFU/g stool) (one-tailed
paired t-test, p=0.006) (Fig. 3). Moreover, for both groups
Clostridium cluster XIVa abundance and the weight for height
parameter were positively correlated (linear mixed model, p=0.03) (Fig. 5). This correlation, however, diminished with age
(linear mixed model, p=0.041). In addition, patients with a low
weight for height parameter revealed much lower abundance of
Clostridium cluster XIVa compared to healthy siblings with a low
weight for height parameter (Fig. 5).
4. Discussion
We previously reported that the predominant fecal microbiota
of childrenwith CF is characterized by a compositional disturbance
of the total fecal microbiota and decreased temporal stability [19].
The present study expanded the 2-year longitudinal study from two
to nine familial units in order to obtain more statistically sound
results, identified the microbial components of the dysbiosis using
band-class analysis of the community fingerprints, and applied
real-time PCR to confirm and quantify the most important
Fig. 5. Clostridium cluster XIVa abundance and weight for height. Scatterplot
displaying the correlation between Clostridium cluster XIVa abundance and
weight for height (%) (linear mixed model, p=0.03).
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Bifidobacterium were temporarily unstable and significantly
underrepresented in the fecal microbiota of patients with CF
in comparison to their healthy siblings. Several studies,
including one of CF patients [32], reported a substantial
decline in the number of GI bifidobacteria during and fo-
llowing antimicrobial supplementation [33–37]. The observed
reduction of bifidobacteria could be the result of their high
antimicrobial susceptibility and reduced adhesion capacity to
inflamed mucosa [38,39]. The results of our DGGE finger-
print analyses revealed a significant reduction of bands
assigned to B. longum, B. catenulatum/B. pseudocatenulatum
and B. adolescentis. These species are considered among the
most important members of the bifidobacterial community in the
GI tract [40]. High bifidobacterial species richness rather than
high abundance is positively correlated with the maturation of the
mucosal immune system [11] but an overall reduction of the
bifidobacteria in children with CF could influence extra-intestinal
disorders such as respiratory inflammation and even infection.
Given the health-promoting features attributed to bifidobacteria
[38,39], their intestinal abundance is also often used as a
biomarker for a well-balanced gut microbiota. Therefore, the
significant decline observed in the present study could have
severe repercussions for the host's health.
We also report for the first time that bacteria of Clostridium
cluster XIVa [31] are significantly underrepresented in the fecal
microbiota of CF patients. Furthermore, in siblings as well as
patients with CF Clostridium cluster XIVa abundance and weight
for height were positively correlated. However, patients with
poorer nutritional status revealed a much lower abundance of
Clostridium cluster XIVa compared to healthy siblings with
poorer nutritional status (Fig. 5). Finally, band-classes 3.79 and
11.46 were underrepresented in samples of patients with CF.
These band-classes were tentatively assigned to R. bromii and F.
prausnitzii, respectively, representing Clostridium cluster IVbacteria [31]. Many Clostridium clusters IV and XIVa bacteria
produce butyrate as a result of carbohydrate fermentation. This
metabolite has various important biological functions such as
providing energy for colonocytes, eliciting an anti-inflammatory
response, establishment and maintenance of the GI barrier, and
reduction of intestinal permeability, and is presumed to be
involved in the prevention of colorectal cancer [41–43]. Yet, the
GI microbial ecosystem has a high level of functional redundancy
and a broad phylogenetic spectrum of bacteria is capable of
synthesizing butyrate. It is therefore unclear to which extent a
significant reduction of these bacterial groups may have clinical
consequences.
Frequent use of high doses of antibiotics such as amoxicillin–
clavulanate likely contributed to the reported dysbiosis. In a study
by Young and Schmidt [44] a considerable decrease in members
of the Clostridium cluster XIVa and of bifidobacteria was noted in
the fecal microbiota of a male patient after treatment with
amoxicillin–clavulanate. Strikingly, whereas the levels of the
former were restored after cessation of antibiotic therapy,
Bifidobacterium concentrations were not. Furthermore, decreased
levels of members of Clostridium clusters IV and XIVa have also
been reported in patients with inflammatory bowel disease
[24,45,46], which could suggest that CF-associated GI inflam-
mation [47–49] may also be involved in the observed dysbiosis.
Although intensive antimicrobial treatment courses are likely
to contribute to the dysbiosis in patients with CF, highly
personalized antibiotic therapies did not allow correlating the
use of specific antimicrobial compounds with a significant
reduction of the bacterial groups. Furthermore, no significant
correlation was found between fecal bacteria and FEV1, FCV or
gender. However, it should be noted that the cohorts in the
present study were not age-matched, and gender-matched, thus
limiting our evaluations.
To our knowledge, this is the first study that identifies specific
bacterial groups as main determinants for a dysbiosis in patients
with CF. The observed underrepresentation and temporal instabil-
ity of members of the genus Bifidobacterium and Clostridium
clusters IV and XIVa in patients with CF could be the result from
the disease-related impairment of essential gastrointestinal func-
tions as well as the detrimental effects of intensive antimicrobial
treatment courses. Further exploration of this dysbiosis at the
functional level is needed to help establish the role of these
bacterial groups and may lead the way to alternative nutritional
interventions with functional foods.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jcf.2012.10.003.
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